Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13301476 | 0.92 | L3MBTL1 (0.72) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13301485 | 0.90 | L3MBTL1 (0.69) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13301464 | 0.90 | L3MBTL1 (0.69) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13301467 | 0.88 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13301471 | 0.88 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13301457 | 0.88 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13301475 | 0.88 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30646241 | 0.87 | L3MBTL1 (0.66) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12431397 | 0.87 | SMN1; SMN2 (0.72) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14582494 | 0.86 | L3MBTL1 (0.65) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | CIBA CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | CIBA CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008107347-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-7374749-B2 | Amino substituted hydroxyphenyl benzophenone derivatives | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7374749-B2 | Amino substituted hydroxyphenyl benzophenone derivatives | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | MAOA, MAOB, ACMSD | L3MBTL1 4501/4885MEN1 237/4885KMT2A 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.